The global monoclonal gammopathy of undetermined significance (MGUS) management market is expected to garner a market value of USD 27 million in 2023 and is expected to accumulate a market value of USD 53.11 million by registering a CAGR of 7% in the forecast period 2023 to 2033. The market for Monoclonal Gammopathy of Undetermined Significance (MGUS) Management registered a CAGR of 4% in the historical period 2018 to 2022.
The monoclonal gammopathy of undetermined significance (MGUS) management market is a segment of the healthcare industry that deals with the effective management of the condition. The market offers a range of products and services for its effective management and treatment such as immunomodulatory drugs and proteasome inhibitors, Chemotherapy, and Stem cell transplant.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 27 million |
| Anticipated Forecast Value (2033) | USD 53.11 million |
| Projected Growth Rate (2023 to 2033) | 7% CAGR |
According to market research and competitive intelligence provider, Future Market Insights- the market for Monoclonal Gammopathy of Undetermined Significance (MGUS) Management reflected a value CAGR of 4% during the historical period, 2018 to 2022.
The market for Monoclonal Gammopathy of Undetermined Significance (MGUS) Management is gaining prominence as it is considered a precancerous condition that progresses to a more serious blood cancer like multiple myeloma, but this progression is not always the case. Furthermore, the increasing incidence of blood cancers and the need for improved diagnosis and treatment options, is expected to drive demand for these treatments.
In its new study, Future Market Insights (FMI) offers insights about key factors driving demand for Monoclonal Gammopathy of Undetermined Significance (MGUS) Management. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Monoclonal Gammopathy of Undetermined Significance (MGUS) Managements is fuelling the market growth. Thus, the market for Monoclonal Gammopathy of Undetermined Significance (MGUS) Management is expected to register a CAGR of 7% in the forecast period 2023 to 2033.
Growing advancements in diagnostic and treatment options of MGUS to push the market growth
The global market for monoclonal gammopathy of undetermined significance (MGUS) management is primarily driven by the incidence of blood cancers, including multiple myeloma, the development of new and effective treatment options, advancements in treatment technologies and development of new diagnostic technologies and the availability of more effective treatments.
According to American Cancer Society estimates in January 2022, about 60,650 new cases of leukemia and 24,000 deaths from leukemia and there were around 11,450 deaths due to acute myeloid leukemia in the United States in the year 2022. Aging population is another factor contributing to the growth of the Monoclonal Gammopathy of Undetermined Significance (MGUS) Management market. As people get older, their risk of developing conditions increases, which is expected to drive demand for these treatments. The prevalence of Monoclonal Gammopathy of Undetermined Significance (MGUS) Management (HE) has increased in recent years, driven by a combination of demographic, technological, and awareness factors.
For instance, in December 2020, the Leukemia and Lymphoma Society (LLS) initiated a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly USD 17 million in research grants, to progress the research in finding effective treatment options for patients with leukemia, lymphoma, myeloma, and other blood cancers.
Expensive Cost of Treatment to restrict Market Growth
The market is projected to get significantly affected by challenging factors such as limited availability and high cost of advanced Monoclonal Gammopathy of Undetermined Significance (MGUS) Management options.
Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, are expected to hinder the market growth. Furthermore, poor healthcare infrastructure, especially in developing countries, can limit access to Monoclonal Gammopathy of Undetermined Significance (MGUS) Management and the availability of diagnostic and therapeutic options.
Improvement in healthcare spending propelling growth of the market in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a share of 20% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Monoclonal Gammopathy of Undetermined Significance (MGUS) Management Market in the region. Asia Pacific is an emerging market due to the increase in point of care approach to health & care. Increasing number of hospitals in India and China makes a promising market for the market worldwide.
Increasing Prevalence of Skin Conditions Shaping Landscape for Monoclonal Gammopathy of Undetermined Significance (MGUS) Management in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region along with the high healthcare expenditure and a large geriatric population. The United States of America holds the highest share in the North American market, followed by Canada.
Presence of a large number of pharmaceutical companies, which are investing heavily in the development of new, targeted treatments for the condition, high level of healthcare expenditure and a growing aging population are some of the factors responsible for the growth of the market in the region.
Hospitals to take the lead and drive market growth
According to the FMI analysis, Hospital pharmacy accounts for the largest market share. The requirement for several hospital stays and visits during the monoclonal gammopathy of undetermined significance (MGUS) management treatment facilitates the growth of this segment.
The majority of the serious venous diseases involving blood clotting are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
Key start-ups in the monoclonal gammopathy of undetermined significance (MGUS) management market include-
Key players in the market include pharmaceutical companies such as Janssen Biotech, Inc., Pfizer, Inc., Amgen, Inc., Roche Holding AG, Celgene Corporation (Acquired by Bristol-Myers Squibb), Novartis AG, Merck & Co., Inc., Sanofi S.A, Takeda Pharmaceutical Company Limited and Gilead Sciences, Inc. along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 27 million |
| Market Value in 2033 | USD 53.11 million |
| Growth Rate | CAGR of 7% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Diagnosis, Distribution Channel, End User, Region |
| Regions Covered |
North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, Malaysia, India, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | PhaseBio Pharmaceuticals Inc.; Pfizer Inc.; Amgen Inc.,; Array Biopharma Inc.; AstraZeneca; Sanofi-Aventis US LLC; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Siemens Healthcare Private Limited; HYCOR Biomedical, Inc.; Omega Diagnostics Group PLC |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 5: Global Market Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 9: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 10: North America Market Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 13: Latin America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 14: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 15: Latin America Market Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 18: Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 19: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 20: Europe Market Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 23: South Asia Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 24: South Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 25: South Asia Market Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 26: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 27: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 28: East Asia Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 29: East Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 30: East Asia Market Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 31: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 32: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 33: Oceania Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 34: Oceania Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 35: Oceania Market Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 36: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 37: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 38: MEA Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 39: MEA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 40: MEA Market Value (US$ Million) Forecast by End-user, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by End-user, 2023 to 2033
Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 12: Global Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 15: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 16: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 18: Global Market Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 19: Global Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 21: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 22: Global Market Attractiveness by Diagnosis, 2023 to 2033
Figure 23: Global Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 24: Global Market Attractiveness by End-user, 2023 to 2033
Figure 25: Global Market Attractiveness by Region, 2023 to 2033
Figure 26: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 27: North America Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 28: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 29: North America Market Value (US$ Million) by End-user, 2023 to 2033
Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 37: North America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 40: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 41: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 43: North America Market Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 44: North America Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 46: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 47: North America Market Attractiveness by Diagnosis, 2023 to 2033
Figure 48: North America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 49: North America Market Attractiveness by End-user, 2023 to 2033
Figure 50: North America Market Attractiveness by Country, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 52: Latin America Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 53: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) by End-user, 2023 to 2033
Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 59: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 62: Latin America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 65: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 68: Latin America Market Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 69: Latin America Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 71: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 72: Latin America Market Attractiveness by Diagnosis, 2023 to 2033
Figure 73: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 74: Latin America Market Attractiveness by End-user, 2023 to 2033
Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 76: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 77: Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 78: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 79: Europe Market Value (US$ Million) by End-user, 2023 to 2033
Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 84: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 87: Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 88: Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 90: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 91: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 93: Europe Market Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 94: Europe Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 95: Europe Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 96: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 97: Europe Market Attractiveness by Diagnosis, 2023 to 2033
Figure 98: Europe Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 99: Europe Market Attractiveness by End-user, 2023 to 2033
Figure 100: Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 102: South Asia Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 103: South Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 104: South Asia Market Value (US$ Million) by End-user, 2023 to 2033
Figure 105: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 106: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 109: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 110: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 112: South Asia Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 113: South Asia Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 115: South Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 116: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 118: South Asia Market Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 119: South Asia Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 120: South Asia Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 121: South Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 122: South Asia Market Attractiveness by Diagnosis, 2023 to 2033
Figure 123: South Asia Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 124: South Asia Market Attractiveness by End-user, 2023 to 2033
Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 126: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 127: East Asia Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 128: East Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 129: East Asia Market Value (US$ Million) by End-user, 2023 to 2033
Figure 130: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 131: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 134: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 135: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 137: East Asia Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 138: East Asia Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 140: East Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 141: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 143: East Asia Market Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 144: East Asia Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 145: East Asia Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 146: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 147: East Asia Market Attractiveness by Diagnosis, 2023 to 2033
Figure 148: East Asia Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 149: East Asia Market Attractiveness by End-user, 2023 to 2033
Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 151: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 152: Oceania Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 153: Oceania Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 154: Oceania Market Value (US$ Million) by End-user, 2023 to 2033
Figure 155: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 156: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 159: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 160: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 162: Oceania Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 163: Oceania Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 165: Oceania Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 166: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 168: Oceania Market Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 169: Oceania Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 170: Oceania Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 171: Oceania Market Attractiveness by Drug Class, 2023 to 2033
Figure 172: Oceania Market Attractiveness by Diagnosis, 2023 to 2033
Figure 173: Oceania Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 174: Oceania Market Attractiveness by End-user, 2023 to 2033
Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 176: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 177: MEA Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 178: MEA Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 179: MEA Market Value (US$ Million) by End-user, 2023 to 2033
Figure 180: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 181: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 184: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 185: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 186: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 187: MEA Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 188: MEA Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 189: MEA Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 190: MEA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 191: MEA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 192: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 193: MEA Market Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 194: MEA Market Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 195: MEA Market Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 196: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 197: MEA Market Attractiveness by Diagnosis, 2023 to 2033
Figure 198: MEA Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 199: MEA Market Attractiveness by End-user, 2023 to 2033
Figure 200: MEA Market Attractiveness by Country, 2023 to 2033
The market is estimated to secure a revenue of USD 27 million by 2023.
The market is expected to reach a value of USD 53.11 million by the end of 2033.
The market is predicted to progress at a CAGR of 7% through 2033.
Growing advancements in diagnostic and treatment options of MGUS.
Improvement in healthcare spending propelling market growth in Asia Pacific, with a share of 20% through 2033.
Explore Therapy Area Insights
Monoclonal Gammopathy of Undetermined Significance (MGUS) Management Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
